Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in the United States
2018.Oct.29
OBI Pharma Australia Pty Ltd announces the clearance of Adogloxad Simolenin (OBI-822) for a Phase III clinical study in Australia
2018.Oct.01
OBI received notice from patent attorney’s office that product patent for OBI-822 named "Compound and Compositions of Carbohydrate Vaccine and Uses Thereof" has been approved by Taiwan Intellectual Property Office
2018.Sep.28
Taiwan FDA clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study
2018.Sep.20
Correction on previous announcement: “Clarification on the news article by Commercial Times” to “United Daily News”
2018.Sep.20
Clarification on the news article by Commercial Times
2018.Sep.19
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
2018.Sep.03
OBI Pharma Inc. to attend 2018 industry forum hosted by Masterlink Securities
2018.Aug.15
OBI received notice from patent attorney’s office that product patent for OBI-3424 named "DNA alkylating agents" has been approved by IP Australia
2018.Jul.30
Clarification on the news article by Commercial Times
